This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard **Terms & Conditions** and the **Ethical guidelines** still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

ChemComm

COMMUNICATION

^{68}Ga Chelating Bioorthogonal Tetrazine Polymers for the Multistep labeling of Cancer Biomarkers[§]

Brandon Nichols‡[a], Zhengtao Qin‡[b], Jun Yang[a], David R. Vera*[b], Neal K. Devaraj*[a]

We have developed a ^{68}**Ga metal chelating bioorthogonal tetrazine dextran probe that is highly reactive with *trans*-cyclooctene modified monoclonal antibodies for multistep imaging applications. Confocal microscopy and positron emission tomography (PET) were used to characterize the dextran probe in vitro and in vivo.**

There is clinical interest in the use of readily available positron emitting isotopes to image affinity ligands in vivo via positron emission tomography (PET).[1,2] Though ^{18}F is readily available, the requirement of cyclotron production and harsh labeling chemistry has sparked interest in exploring alternative radionuclides. One of the most promising is ^{68}Ga, which can be conveniently produced on-site using a variety of commercially available generators.[2] Also, unlike ^{18}F, which is covalently attached by harsh substitution chemistry, ^{68}Ga can be readily incorporated into a number of standard chelating agents such as diethylene triamine pentaacetic acid (DTPA). Here we report a novel metal chelating bioorthogonal tetrazine DTPA dextran probe that is capable of being radiolabelled using the positron emitting isotope ^{68}Ga.[3,4] These probes are highly reactive with *trans*-cyclooctene (TCO) modified monoclonal antibodies.[5,6,7] Previous work has established the use of tetrazine bioorthogonal chemistry using 18F radiolabels, however ^{68}Ga offers the ability to directly label tetrazines due to the mild nature of the chelation conditions.[8,9,10] Additionally, ^{68}Ga can be generator


Figure 1: Bioorthogonal inverse Diels-Alder reaction between tetrazine and *trans*-cyclooctene for multistep labeling of cancer cells with tetrazine DTPA dextran containing an imaging agent.

produced, offering advantages over other positron emitting metal isotopes such as ^{64}Cu. However, it was unclear whether tetrazines would be compatible with ^{68}Ga coordination chemistry, as tetrazines themselves can interfere with metal binding ligands.[9] To our knowledge this is the first example of adapting tetrazine bioorthogonal chemistry for use with ^{68}Ga PET imaging. The short half-life of 68Ga is poorly matched with the clearance half-life of monoclonal antibodies.[11] Bioorthogonal labeling using metal-chelating tetrazines could enable use of the generator produced ^{68}Ga radionuclide for the multistep labeling and imaging of monoclonal antibodies bound to cancer related biomarkers.

Previous work has indicated that polymeric scaffolds can improve the efficiency of in vivo reactions by tuning the blood clearance rate.[7] In choosing a polymer scaffold, we decided to explore the use of dextrans due to their well-established clinical safety record, hydrophilicity, low expense, ready availability in numerous molecular weights, and our previous experience working with dextran imaging agents.[7,12,13] Dextrans with amine leashes and radionuclide agents have been extensively studied as radionuclide imaging agents for sentinel lymph node detection.[3,14,15] In order to chelate the ^{68}Ga, we decided to utilize DTPA chelation groups based on prior clinical work with DTPA albumins and dextrans and the known stability of DTPA chelates[16,17] which

[a] Department of Chemistry and Biochemistry
University of California, San Diego, La Jolla, CA, 92093
Email: ndevaraj@ucsd.edu

[b] Department of Radiology,
UCSD In Vivo Cancer and Molecular Imaging Center
University of California, San Diego, La Jolla, CA, 92093
Email: dvera@ucsd.edu

‡ *Both authors contributed equally.*

§*Electronic supplementary information (ESI) available. See DOI: ####/#####*

exhibits adequate in vivo stability for gallium during the moderately short biological half-life of the dextran conjugate.[17,18] However, although the DTPA chelate is suitable for the intended proof-of-principle studies, future clinical implementation of the proposed ^{68}Ga imaging probes would likely utilize alternative chelators.[19,20]

Although a multistep PET imaging approach would have application to numerous disease models, to initially test and optimize our method we chose to work with a human colon cancer model and target the A33 antigen.[21,22] Initially, we were interested in determining whether the chelating tetrazine DTPA dextrans were capable of specifically targeting *trans*-cyclooctene modified monoclonal antibodies bound to the extracellular A33 marker. To verify extracellular localization, we decided to perform fluorescence microscopy studies using tetrazine DTPA dextran modified with a near-infrared emitting fluorescent probe, AlexaFluor 647 (AF647). DTPA dextran containing reactive amine "leashes" was synthesized as previously described and modified with approximately 1 equivalent of AF647.[4] The remaining amines were then modified with 5 equivalents of tetrazine NHS and finally capped by excess acetic anhydride creating AF647 tetrazine DTPA dextran. A33 expressing LS174T human colon cancer cells were targeted with a TCO modified anti-A33 antibody (~5.3 equivalents of TCO per antibody), washed, and subsequently reacted with 10 μM of the fluorescent dextran for 30 minutes. After washing, the cells were imaged using fluorescence microscopy. As shown in Figure 2, the cells surfaces were brightly stained (green), indicating that the fluorescent tetrazine DTPA dextran had modified the surface bound TCO antibodies. Staining is absent inside the cells, indicating that the dextran has not internalized, as expected for the non-internalizing A33 antigen.[23] Control experiments showed minimal surface staining, indicating that the chelating tetrazine DTPA dextrans are highly reactive, with cellular bound dienophiles such as TCO similar to previously introduced tetrazine imaging agents.[24] We also note that previous work has demonstrated that a fluorescent tag does not alter the receptor affinity or in vivo behavior of the receptor-specific dextran conjugate, Tc-99m-labeled Cy7-


Figure 2. Confocal images of cells treated with fluorescent AlexaFluor 647 (AF647) tetrazine DTPA dextran. A) Cells pretargeted with *trans*-cyclooctene anti-A33 (sample). Scale bar (lower right) 15 microns. B) Cells lacking A33/TCO (control).

tilmanocept.[12]

Having demonstrated that tetrazine DTPA dextrans are capable of multistep labeling of strained dienophile modified surface biomarkers, we proceeded to explore metalation of tetrazine DTPA dextran with the positron emitting radionuclide [68]Ga. In contrast to ^{18}F, ^{68}Ga is an emerging generator produced PET radionuclide that, in addition to not requiring a cyclotron, is also appended to molecules via non-covalent and mild chelation chemistry.[25] Thus we expected that tetrazine reactive groups would be compatible with the conditions required for ^{68}Ga chelation of pendant DTPA ligands. [68]Ga was chelated to tetrazine modified DTPA dextran following previously published procedures in 99% radiochemical yield (RCY) (Figure S1a).[3]

We next determined if the resulting ^{68}Ga tetrazine DTPA dextran was suitable for multistep cellular labeling similar to the fluorescent AF647 tetrazine DTPA dextran (Figure S1b). LS174T cells were labeled with *trans*-cyclooctene anti-A33 monoclonal antibodies and subsequently exposed to 40 μCi ^{68}Ga tetrazine DTPA dextran. Radiolabel uptake was quantified and compared to cells that received a control lacking dienophile. We also compared how TCO antibody loading affected the radiolabel similar to the fluorescent AF647 tetrazine DTPA dextran


Figure 3 a) PET reconstruction (coronal slice) after injection of 50μCi of 68Ga dextran tetrazine. b) time-activity curves of liver (squares) and heart (circles). c) Biodistribution of tetrazine dextran after sacrifice.

(Figure S1b). LS174T cells were labeled with *trans*-cyclooctene anti-A33 monoclonal antibodies and uptake. Previous work has demonstrated that stoichiometric amplification of secondary imaging agents can be achieved by increasing the pretargeted monoclonal antibodies.[26] Indeed, decreasing the amount of TCOs that the antibodies were exposed to (30 equivalents versus 50) resulted in decreased ^{68}Ga uptake.

We monitored the in vivo pharmacokinetics and biodistribution of ^{68}Ga tetrazine DTPA dextran with PET imaging followed by sacrifice and measurement of the percent injected dose of ^{68}Ga probe in various tissues of interest. Figure 3a depicts a typical PET image of a mouse 60 minutes after receiving 50 µCi of ^{68}Ga tetrazine dextran. Imaging for mice (n=3) indicated that the tetrazine probe showed moderate clearance and the expected uptake pattern for a DTPA dextran imaging agent in the blood pool. Mice were sacrificed after the 60 minute PET scan, and key organs and tissues were dissected, weighed, and the radioactivity counted to determine the percent injected dose (Figure 3b). We estimate that the blood half-life of the ^{68}Ga tetrazine dextran to be slightly less than one hour. Thus, this agent should be compatible with the 68 minute decay half-life of [68]Ga. Blood stability tests were performed in human plasma with ^{68}Ga DTPA Dextran. It was found that, after a 3 hour incubation period, no free ^{68}Ga was present in the plasma. Thus, the stability is compatible with the blood clearance times and tetrazine modification does not have a significant effect on ^{68}Ga DTPA dextran distribution in vivo.

Preliminary PET studies demonstrated the ability of ^{68}Ga tetrazine dextrans to target A33 biomarkers in in vivo subcutaneously implanted LS174T xenografts. Xenograft bearing mice were injected with TCO modified anti-A33 bearing a near-IR fluorescent dye. After 24 hours, the ^{68}Ga tetrazine DTPA probe was injected, followed by PET imaging, sacrifice, and fluorescence imaging of relevant tissue samples. A tumor to muscle ratio (%injected dose/gram) of 3.9 ± 1.8 was obtained. Our proposed multistep approach is highly modular, and it is conceivable that alternative tetrazines, chelators, polymers, and dienophiles may be utilized to improve signal to background. Indeed, although DTPA chelates are adequate for these initial proof-of-principle studies, clinical implementation would likely make us of more stable gallium chelators such as NOTA.[19,20] We believe that tetrazine dextrans may eventually enable the multistep labeling of a broad array of surface biomarkers using the convenient short-lived PET radioisotope [68]Ga.

Notes and references

1. S. S. Gambhi, *Nature Reviews*, 2002, **2**, 683-693.
2. C. L. Ferreira, E. Lamsa, M. Woods, Y. Duan, P. Fernando, C. Bensimon, M. Kordos, K. Guenther, P. Jurek, G. E. Kiefer, *Bioconjug Chem*, 2010, **21(3)**, 531-536.
3. S. P. Stroup, C. J. Kane, S. Farchshchi-Heydari, C.M. James, C. H. Davis, A. M. Wallace, C. K. Hoh, D. R. Vera, *Clin Exp Metastasis*.2012, **29**, 673–680.
4. D. R. Vera, A. M. Wallace, C. K. Hoh, R. F. Mattrey, *J Nucl Med*, 2001, **42**, 951–959.
5. R. Rossin, P. R. Verkerk, S. M van den Bosch, R. C. Vulders, I. Verel, J. Lub, M. S. Robillard, *Angew. Chem*, 2010, **122**, 3447–3450.
6. B.M. Zeglis, K. K. Sevak, T. Reiner, P. Mohindra, S. D. Carlin, P. Zanzonico, R. Weissleder, J. S. Lewis, *J Nucl Med*, 2013, **54**, 1389-1396.
7. N. K. Devaraj, G. M. Thurber, E. J. Keliher, B. Marinelli, R. Weissleder, *Proc Natl Acad Sci U S A*, 2012, **109**, 4762–4767.
8. S. Liu, M. Hassink, R. Selvaraj, L.P. Yap, R. Park, H. Wang, X. Chen, J. M. Fox, Z. Li, P. S. Conti, *Molecular Imaging,* 2013, **12(2)**, 121-128.
9. R. Selvaraj, S. Liu, M. Hassink, C. Huang, L. Yap, R. Park, J. M. Fox, Z. Li, P. S. Conti, *Bioorg Med Chem Lett,* 2011, **21(17)**, 5011-5014.
10. Z. Li, H. Cai, M. Hassink, M. L. Blackman, R. C. D. Brown, P. S. Conti, J. M. Fox. *Chem. Commun.,*2010, **46**, 8043-8045.
11. D. A. Goodwin, C. F. Meares, M. McTigue, W. Chaovapong, C. I. Diamanti, C. H. Ransone, M. J. McCall, *J Nucl Med*, 1992, **33**, 2006-2013.
12. L. Thoren, Prog Clin Biol Res, 1978, **19**, 265–282.
13. J. Varshosaz, *Expert Opin Drug Deliv*,2012, **9**, 509–523.
14. D. K. Emerson, K. K. Limmer, D. J. Hall, S. H. Han, W. C. Eckelman, C. J. Kane, A. M. Wallace, D. R. Vera, *Radiology*, 2012, **265**, 186–193.
15. A. M. Wallace, C. K. Hoh, S. J. Ellner, D. D. Darrah, G. Schulteis, D. R. Vera, *Ann Surg Oncol*, 2007, **14**, 913–921.
16. K. Torizuka, S. K. Ha-Kawa, M. Kudo, Y. Kubota, K. Yamamoto, K. Itoh, K. Nagao, G. Uchiyama, K. Koizumi, Y. Sasaki, et al, *Kaku Igaku*,1992, **29**, 159–181.
17. T. Qu, Y. Wang, Z. Zhu, M. Rusckowski, D. J. Hnatowich, *Nucl Med Commun*, 2001, **22**, 203–215.
18. R.Haubner, D. R. Vera, S. Farshchi-Heydari, A. Helbok, C. Rangger, D. Putzer, I. J. Virgolini, *Eur J Nucl Med Mol Imaging*, 2013, **40**, 1245-1255.
19. C. L. Ferreira, E. Lamsa, M. Woods, Y. Duan, P. Fernando, C. Bensimon, M. Kordos, K. Guenther, P. Jurek, G. E. Kiefer, *Bioconjug Chem*, 2010, **21(3)**, 531-536.
20. C. L. Ferreira, D. T. Yapp, D. Mandel, R. K. Gill, E. Boros, M. Q. Wong, P. Jurek, G. E. Kiefer, *Bioconjug Chem*, 2012, **23**, 2239–2246.
21. E. C. Barendswaard, J. L. Humm, J. A. O'Donoghue, G. Sgouros, R. D. Finn, A. M. Scot, S. M. Larson, S. Welt, *J Nucl Med*, 2001, **42**, 1251–1256.
22. F. T. Lee, C. Hall, A. Rigopoulos, J. Zweit, K. Pathmaraj, G. J. O'Keefe, F. E. Smyth, S. Welt, L. J. Old, A. M. Scott, *J Nucl Med*, 2001, **42**, 764–769.
23. M. E. Ackerman, C. Chalouni, M. M. Schmidt, V. V. Raman, G. Ritter, L. J. Old, I. Mellman, K. D. Wittrup, *Cancer Immunol Immunother*, 2008, **57**, 1017–1027.
24. N. K. Devaraj, R. Weissleder, *Accounts Chem Res*, 2011, **44**, 816–827.
25. C. S. Cutler, N. Sisay, M. Cantorias, F. Galazzi, T. P. Quinn, C. J. Smith, *Radiochim Acta*, 2011, **99**, 641–651.
26. N. K. Devaraj, R. Upadhyay, J. B. Hatin, S. A. Hilderbrand, R. Weissleder, *Angew Chem Int Edit*, 2009, **48**, 7013–7016.